Media Articles Related to Oxyir (Oxycodone)
Tough-to-Abuse Formulation of Oxycodone Approved
Source: MedicineNet Chronic Pain Specialty [2014.07.25]
Title: Tough-to-Abuse Formulation of Oxycodone Approved
Category: Health News
Created: 7/24/2014 12:36:00 PM
Last Editorial Review: 7/25/2014 12:00:00 AM
FDA Approves Abuse-Deterrent Oxycodone/Naloxone Combo
Source: Medscape NeurologyHeadlines [2014.07.23]
The FDA has approved an abuse-deterrent extended-release formulation of oxycodone (Targiniq ER, Purdue Pharma LP), a combination of oxycodone hydrochloride and naloxone hydrochloride.
Shrinking oral cancers with anti-pain agent spares healthy tissues
Source: Cancer / Oncology News From Medical News Today [2014.07.25]
Mouse models of human oral cancer treated with an agent called capsazepine showed dramatic tumor shrinkage without damage to surrounding tissues, researchers from the School of Dentistry and School...
Severe pain during and post delivery linked to postpartum depression
Source: Depression News From Medical News Today [2014.07.25]
Controlling pain during childbirth and post delivery may reduce the risk of postpartum depression, writes Katherine Wisner, M.D.
Research led by Temple's Chair of dermatology shows that pain and itch may be signs of skin cancer
Source: Medical Devices / Diagnostics News From Medical News Today [2014.07.25]
Asking patients if a suspicious skin lesion is painful or itchy may help doctors decide whether the spot is likely to be cancerous, according to a new study headed by Gil Yosipovitch, MD, Chairman...
Published Studies Related to Oxyir (Oxycodone)
Tolerability and efficacy of two synergistic ratios of oral morphine and
oxycodone combinations versus morphine in patients with chronic noncancer pain. 
SETTING: Clinical study centers in Australia... CONCLUSION: A 3:2 or 1:2 fixed ratio combination of morphine and oxycodone (MOX)
Liver cancer: effects, safety, and cost-effectiveness of controlled-release
oxycodone for pain control after TACE. 
liver cancer who are undergoing transarterial chemoembolization... CONCLUSION: CRO is effective, safe, and cost-effective in the control of
A randomized, double-blind, active-controlled, double-dummy, parallel-group study
to determine the safety and efficacy of oxycodone/naloxone prolonged-release
tablets in patients with moderate/severe, chronic cancer pain. 
prolonged-release tablets (OxyPR) in patients with moderate/severe cancer pain... CONCLUSIONS: OXN PR provides superior bowel function in cancer pain patients,
Oxycodone lengthens reproductions of suprasecond time intervals in human research volunteers. [2011.08]
Oxycodone, a popularly used opioid for treating pain, is widely abused. Other drugs of abuse have been shown to affect time perception, which, in turn, may affect sensitivity to future consequences.
Clinical outcomes during opioid titration following initiation with or conversion to Remoxy(R), an extended-release formulation of oxycodone. [2011.07]
Intra- and interpatient variability in opioid response usually necessitates opioid therapy titration to optimally balance analgesia and side effects, whether initiating therapy or converting from another opioid. Remoxy(R) (King Pharmaceuticals, Inc., Bristol, TN, which was acquired by Pfizer Inc in March 2011) is an extended-release formulation of oxycodone designed to maintain its rate-controlling mechanism following physical and chemical manipulation...
Clinical Trials Related to Oxyir (Oxycodone)
Oxycodone for Labor Pain - Pharmacokinetics (PK), Safety and Efficacy [Not yet recruiting]
Childbirth is one of the most painful events that a woman is likely to experience, and thus
is a major concern for most parturient. Severe pain releases stress mediators and may thus
compromise fetus well-being if placental perfusion is decreased. Epidural analgesia is the
golden standard for the management of severe labor pain. However, it could not always be
used both due the parturient related factors and the organizational reasons. However, the
knowledge on safety and efficacy of oxycodone involving mother, fetus and newborn is
Aim of the study is firstly, to evaluate the efficacy and safety of oxycodone in labor pain
healthy parturients. Secondly, to measure parturient's blood oxycodone concentration during
labour and fetal concentration from placental umbilical vein and artery right after birth.
Comparison of the Efficacy of Oral Oxycodone and Oral Codeine in the Treatment of Postcraniotomy Pain [Recruiting]
The efficacy of codeine is dependent on its demethylation to morphine. This extent of
demethylation has wide inter-individual variability, making codeine's efficacy as a
analgesic variable. Oxycodone is a semi-synthetic opioid and is a weak agonist on mu opioid
Codeine has been the mainstay of analgesia for patients after craniotomy for many years.
Traditionally, craniotomies were not thought to be very painful procedures, hence the use of
codeine, a moderately potent opioid (when compared to morphine).
However, in recent years, it has been found that up to 70% of post-craniotomy patients have
moderate to severe pain and codeine did not provide adequate analgesic relief. Many studies
have compared codeine to other drugs such as PCA morphine, fentanyl and tramadol, and
patients on these stronger opioids generally had lower pain scores and better satisfaction.
No study has been conducted to determine the efficacy of analgesia of oral oxycodone to oral
Hence, the hypothesis is that oxycodone is more effective than codeine in providing pain
relief in post-craniotomy patients.
Oxycodone-Naloxone Prolonged Release Tablets in Relieving Opioid-Related Constipation [Active, not recruiting]
Oxycodone-Naloxone in Relieving Opioid-Related Constipation [Active, not recruiting]
The primary objective of this study is to demonstrate that subjects with moderate to severe
non-malignant pain taking oxycodone/naloxone prolonged release tablets have improvement in
symptoms of constipation compared to subjects taking oxycodone prolonged release tablets
Open-Label Trial Comparing Oxycodone Medications [Recruiting]
The investigators hypothesize that subjects will have greater pain relief when taking
IR-oxycodone compared with ER-oxycodone for several reasons. The ability to take a varying
amount of medication at six different points over the course of a day will allow patients to
take as much (or as little) medication as they need to control their pain. In addition, the
ability to vary the medication doses in this way will give them a greater sense of control,
which will also contribute to greater pain relief. Similarly, the investigators predict that
patients will show greater benefits with IR-oxycodone on the measures of physical and
emotional functioning. Because there is relatively little data on sleep apnea in chronic
pain patients (Webster et al., 2008), these assessments are exploratory and not
hypothesis-based. Finally, although it is typically thought that the abuse liability of
IR-opioid medications is greater than for ER-medications, the data on which this belief are
based have not involved systematic studies of patients with chronic pain; the assessments of
abuse liability will therefore also be exploratory.